J
Jean-Jacques Wyndaele
Researcher at University of Antwerp
Publications - 201
Citations - 7377
Jean-Jacques Wyndaele is an academic researcher from University of Antwerp. The author has contributed to research in topics: Urinary bladder & Overactive bladder. The author has an hindex of 40, co-authored 192 publications receiving 6640 citations.
Papers
More filters
Journal ArticleDOI
Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC Proposal
Joop P. van de Merwe,Jørgen Nordling,Pierre Bouchelouche,Kirsten Bouchelouche,Mauro Cervigni,L. Kurosch Daha,Suzy Elneil,Magnus Fall,Gero Hohlbrugger,Paul P. Irwin,S. A. Mortensen,Arndt van Ophoven,John L. Osborne,Ralph Peeker,Benedikte Richter,Claus R. Riedl,Jukka Sairanen,Martina Tinzl,Jean-Jacques Wyndaele +18 more
TL;DR: The name IC has become misleading and is replaced by BPS, in line with recent nomenclature recommendations by the European Association of Urology and based on the axial structure of the International Association for the Study of Pain classification.
Journal ArticleDOI
EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction
Manfred Stöhrer,Bertil F.M. Blok,David Castro-Diaz,E. Chartier-Kastler,Giulio Del Popolo,G. Kramer,Jürgen Pannek,Piotr Radziszewski,Jean-Jacques Wyndaele +8 more
TL;DR: The diagnosis and treatment of NLUTD, which is a highly specialised and complex field involving both urology and medicine, requires up-to-date expert advice to be readily available and the current guidelines are designed to fulfil this need.
Journal ArticleDOI
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.
Apostolos Apostolidis,Prokar Dasgupta,Pierre Denys,Sohier Elneil,Clare J. Fowler,Antonella Giannantoni,Gilles Karsenty,Heinrich Schulte-Baukloh,Brigitte Schurch,Jean-Jacques Wyndaele +9 more
TL;DR: The consensus committee recommends larger placebo-controlled and comparative trials to evaluate the efficacy of single and repeat injections, the duration of effect, the optimal dosage and injection technique, the timing for repeat injection, and the short- and long-term safety of the treatment in LUT and pelvic-floor disorders.
Journal Article
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Christopher R. Chapple,Jean-Jacques Wyndaele,Jørgen Nordling,F. Boeminghaus,A. F. G. V. M. Ypma,Paul Abrams +5 more
TL;DR: Tamsulosin 0.4 mg once daily is safe, well-tolerated and improves both the symptoms and urinary flow rate in patients with benign prostatic obstruction (symptomatic BPH).
Journal ArticleDOI
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action†‡
Karl-Erik Andersson,William C. de Groat,Kevin T. McVary,Tom F. Lue,Mario Maggi,Claus G. Roehrborn,Jean-Jacques Wyndaele,Thomas Melby,Lars Viktrup +8 more
TL;DR: This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.